FDA approves Bristol Myers Squibb's schizophrenia drug
WEB10 hours ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more...
Bristol Myers Squibb - News
WEBSep 9, 2024 · Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
US FDA approves Bristol Myers' schizophrenia drug | Reuters
WEB10 hours ago · Sept 26 (Reuters) - The U.S. FDA approved Bristol Myers Squibb's (BMY.N) schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental...
U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB8 hours ago · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride),...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB1 day ago · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a f...
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult ...
WEB7 hours ago · (RTTNews) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia …
WEB10 hours ago · Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
FDA approves Bristol schizophrenia drug that could alter how
WEB10 hours ago · The drug, called Cobenfy, will be sold by Bristol Myers Squibb. It was developed by the biotech company Karuna Therapeutics, which Bristol acquired for $14 billion last year.
Bristol Myers Squibb - Bristol Myers Squibb Completes …
WEBMar 18, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
Pharmaceutical press releases & news - Bristol Myers Squibb
WEBExplore Bristol Myers Squibb's latest press releases to learn more about our company, our medicines, research innovation and other news as we work to support patients fighting serious disease.